Research
Hormonal
Fecal microbiota transplantation (FMT) from lean donors transiently improves insulin sensitivity and glucose metabolism in patients with metabolic syndrome, though effects often diminish after 18 weeks without maintenance.
FMT from lean donors can significantly boost insulin sensitivity and lower blood sugar in metabolic syndrome patients, but these benefits are temporary (lasting ~6 weeks) and may require repeated treatments or maintenance fiber. It is not a one-time cure and is currently expensive.
ModerateQualifiesMEDIUM confidence
Significant insulin sensitivity improvement at 6 wks; not sustained at 18 wks... Small-intestinal infusion; primary observation at 6 wk... Replicates short-term benefits but effect fades.
Why this rating
Supported by multiple RCTs and meta-analyses, but sample sizes are small and long-term data is lacking.
Source
Harnessing Microbiome Therapy to Treat Metabolic Syndrome
Mustafa Al Jnainati et al. · AACE Endocrinology and Diabetes · 2026
DOI 10.1016/j.aed.2025.11.015
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions (diet and exercise) remain the most cost-effective and durable strategy for weight loss and diabetes prevention, outperforming microbiome therapies in long-term weight management.Strong
- Probiotic and synbiotic supplementation improves glycemic control, lipid profiles, and reduces inflammation in patients with type 2 diabetes and obesity, with strain-specific effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →